TMEM42 Inhibitors
TMEM42 Inhibitors encompass a range of chemical compounds that impede the functionality of the TMEM42 protein via distinct cellular mechanisms. Compounds such as Rapamycin and LY 294002 operate by attenuating the PI3K/AKT/mTOR and PI3K pathways, respectively; pathways that are integral to regulating protein synthesis and cellular growth, where TMEM42 presumably plays a role. Similarly, PD 98059 and U0126, which are inhibitors of MEK, can lead to the downregulation of TMEM42 activity by preventing the activation of the MAPK/ERK pathway, a potential regulator of TMEM42. The broad-spectrum kinase inhibitor Staurosporine, as well as W-7, a calmodulin antagonist, can disrupt the phosphorylation state and calcium-mediated regulation of TMEM42, respectively, thereby reducing its activity. In addition, Brefeldin A and Tunicamycin hinder the trafficking and post-translational modifications of TMEM42 by disrupting Golgi apparatus function and inhibiting N-linked glycosylation, leading to a decrease in TMEM42's functional activity.
Furthermore, Thapsigargin, with its ability to disrupt calcium homeostasis by inhibiting the SERCA pump, could negatively impact TMEM42 if it relies on calcium-dependent signaling. The glycolytic inhibitor 2-Deoxy-D-glucose may indirectly reduce TMEM42 activity by impeding cellular energy production, potentially affecting energy-dependent functions of the protein. Cycloheximide contributes to the diminution of TMEM42's functional activity by broadly inhibiting protein synthesis, while Chloroquine, by increasing endosomal pH, could interfere with TMEM42 if its activity is pH-sensitive. Collectively, these inhibitors leverage a variety of biochemical pathways to reduce the functional activity of TMEM42, thereby providing a multifaceted approach to the inhibition of this protein without directly altering its expression levels.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can diminish the signaling in the PI3K/AKT/mTOR pathway, which is crucial for various cellular processes including protein synthesis and cell survival. By inhibiting mTOR, rapamycin indirectly leads to reduced functional activity of TMEM42, which may be implicated in these cellular processes. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent protein kinase inhibitor, which targets a wide range of kinases. By inhibiting protein kinases that are potentially involved in the phosphorylation state and activation of TMEM42, staurosporine indirectly decreases TMEM42 activity. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
An inhibitor of ADP-ribosylation factor (ARF), which disrupts the function of the Golgi apparatus. Since TMEM42 is a transmembrane protein, its trafficking and function could be indirectly diminished by brefeldin A through Golgi disruption. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
An inhibitor of N-linked glycosylation. If TMEM42 requires glycosylation for its stability or activity, tunicamycin would indirectly decrease its functional activity by preventing proper post-translational modification. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
A glucose analog that inhibits glycolysis by inhibiting hexokinase. This compound can indirectly lead to diminished energy supply in cells, which may affect the activity of energy-dependent proteins like TMEM42. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Inhibits eukaryotic protein synthesis by interfering with the translocation step in protein synthesis on ribosomes. While not directly inhibiting TMEM42, it can decrease its functional activity by reducing overall protein synthesis. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A specific inhibitor of MEK, which acts upstream in the MAPK/ERK pathway. If TMEM42 is regulated or activated by the MAPK/ERK pathway, PD 98059 would lead to a decrease in TMEM42 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of PI3K, which is upstream of the AKT signaling pathway. By inhibiting PI3K, LY 294002 indirectly decreases TMEM42 activity if TMEM42 is involved in this signaling pathway. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
A sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) pump inhibitor, which disturbs calcium homeostasis in cells. Disruption of calcium signaling can indirectly diminish the activity of TMEM42 if it is calcium-dependent. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A selective inhibitor of MEK1/2, which prevents the activation of the ERK pathway. If TMEM42 activity is associated with the ERK pathway, U0126 would indirectly diminish its activity. | ||||||